Status:
UNKNOWN
EUS-guided Ethanol-lipiodol Ablation of Pancreatic Neuroendocrine Tumor: a Prospective Study
Lead Sponsor:
Asan Medical Center
Collaborating Sponsors:
Dankook University
Conditions:
Efficacy
Safety
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
The present study evaluate the safety and efficacy of EUS-guided ethanol-lipiodol ablation for the treatment of pancreatic NET
Detailed Description
Pancreatic neuroendocrine tumor, including insulinoma, increasingly are being encountered in clinical practice. Management of pancreatic NET is challenging because most are asymptomatic but may have m...
Eligibility Criteria
Inclusion
- Pancreas NET(including insulinoma) \< 2cm in diameter
- Poor surgical candidate (involving the head of the pancreas or multifocal NET, advanced comorbidity, age \>75 years of age)
- Refuse to surgery
Exclusion
- Younger than 18 years of age
- Coagulopathy (INR \>1.5, Platelet \<50,000)
- Evidence of active pancreatitis
- Inability to safely undergo EUS
- Refuse to participate
Key Trial Info
Start Date :
July 1 2013
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 1 2017
Estimated Enrollment :
34 Patients enrolled
Trial Details
Trial ID
NCT01902238
Start Date
July 1 2013
End Date
August 1 2017
Last Update
December 1 2016
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Asan Medical Center
Seoul, South Korea, 138-736